Assetmark Inc. Sells 1,880,494 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Assetmark Inc. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 86.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 296,870 shares of the biopharmaceutical company’s stock after selling 1,880,494 shares during the period. Assetmark Inc.’s holdings in Gilead Sciences were worth $27,422,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the 4th quarter worth $31,000. Finally, Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This represents a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 293,356 shares of company stock worth $29,166,240 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.6 %

Shares of Gilead Sciences stock opened at $115.44 on Thursday. The stock has a market capitalization of $143.87 billion, a P/E ratio of 312.00, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a 50-day simple moving average of $98.71 and a 200 day simple moving average of $90.91. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $117.39.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.74%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Robert W. Baird upped their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Morgan Stanley increased their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.24.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.